BioWorld

April 28, 2008

View Archived Issues

Astellas, CoMentis in $760M Deal for Alzheimer's Treatment

Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today) Read More

FDA OKs Progenics Drug; EMA also Gives It a Nod

Read More

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

Read More

Observational Trials Have Merits, but Stark Limits also Apparent

Read More

Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab

Read More

Isis Shares Slip on Need for Mipomersen Data

Read More

House Measure Reauthorizes BIO-Backed SBIR Grants

Read More

Other News To Note

Read More

Clinic Roundup

Read More